Bvf Inc Lexicon Pharmaceuticals, Inc. Transaction History

Bvf Inc

$3.34 Billion
Q1 2024

A detailed history of Bvf Inc transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Bvf Inc holds 1,686,924 shares of LXRX stock, worth $2.83 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

1,686,924

Previous 24,435,632 93.1%

Holding current value

$2.83 Million

Previous $37.4 Million 89.17%

% of portfolio

0.12%

Previous 0.98%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.3 - $3.58 $29.6 Million - $81.4 Million	-22,748,708 Reduced 93.1%	1,686,924 $4.05 Million
Q4 2023 Feb 14, 2024	BUY	$1.0 - $1.53 $4.44 Million - $6.79 Million	4,440,300 Added 22.21%	24,435,632 $37.4 Million
Q2 2023 Aug 14, 2023	BUY	$2.15 - $3.49 $8.27 Million - $13.4 Million	3,846,153 Added 23.82%	19,995,332 $45.8 Million
Q3 2022 Nov 14, 2022	BUY	$1.94 - $3.43 $3.88 Million - $6.86 Million	2,000,000 Added 14.14%	16,149,179 $38.8 Million
Q2 2022 Aug 15, 2022	SELL	$1.31 - $2.69 $271,707 - $557,932	-207,410 Reduced 1.44%	14,149,179 $26.3 Million

Q1 2022 May 16, 2022	SELL	$1.95 - $3.89 $6,651 - $13,268	-3,411 Reduced 0.02%	14,356,589 $30 Million
Q3 2021 Nov 15, 2021	BUY	$3.38 - $5.35 $20.2 Million - $31.9 Million	5,966,000 Added 71.07%	14,360,000 $69.1 Million
Q1 2021 May 17, 2021	SELL	$3.45 - $9.09 $8.86 Million - $23.4 Million	-2,569,000 Reduced 23.43%	8,394,000 $49.3 Million
Q4 2020 Feb 12, 2021	BUY	$1.05 - $3.67 $11.5 Million - $40.2 Million	10,963,000 New	10,963,000 $37.5 Million

Others Institutions Holding LXRX

# of Institutions

122

Shares Held

159M

Call Options Held

2.11M

Put Options Held

412K

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $317M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bvf Inc with notifications on news.

Account